geht hier was

es geht weiter voran und die Zeit drängt ! Könnte bald zu positiven Ergebnissen
führen und eine Zulassung in Kürze erfolgen . Dann kommt noch die ADR freigabe
Nasdaq die ermöglicht institutionellen Anlegern die nicht am OTC handeln zu
investieren ! Es bleibt sehr sehr spannend ! :-)

https://clinicaltrials.gov/ct2/show/...viptadil&draw=2&rank=6  

Angeblich wegen zuwenig Patientendaten . NIH läuft gut und
wir können nur hoffen das der crash nicht zu heftig wird . NRXP
bis jetzt minus 50% !!! Schade fing gerade wieder gut an ! :-(


https://www.nrxpharma.com/...tical-covid-19-with-respiratory-failure/  

Schade mein Geld ist weg.
 

 
Ad hoc announcement pursuant to Art. 53 LR  
1

Relief Reports that its U.S. Collaboration Partner’s Emergency Use Authorization
Request  for  ZYESAMI®/RLF-100™  (aviptadil)  for  Patients  with  Critical  COVID-19
with Respiratory Failure was Declined by the U.S. Food & Drug Administration  

Geneva,  Switzerland,  November  5,  2021  –  RELIEF  THERAPEUTICS  Holding  SA  (SIX:  RLF,  OTCQB:  RLFTF)
(“Relief”),  a  biopharmaceutical  company  seeking  to  provide  patients  therapeutic  relief  from  serious
diseases with high unmet need, reported today that the parent company of its U.S. collaboration partner,
NRx  Pharmaceuticals,  Inc.,  (Nasdaq: NRXP) (“NRx”),  has  issued  a  press  release  announcing  that  it  was
declined Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the use
of IV aviptadil for the treatment of acute respiratory failure due to critical COVID-19. The related NRx press
release can be accessed through the following link.  

ABOUT RELIEF
Relief  focuses  primarily  on  clinical-stage  programs  based  on molecules with  a  history  of  clinical  testing
and use in human patients or a strong scientific rationale. Relief’s lead drug candidate, RLF-100TM
(aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S.
for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy,  
in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the
worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate
release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle
Disorders  and  Maple  Syrup  Urine  Disease.  In  addition,  Relief's  recently  completed  acquisitions  of  APR
Applied Pharma Research SA and AdVita Lifescience GmbH bring to Relief a diverse pipeline of marketed
and development-stage programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in
the  U.S.  on  OTCQB  under  the  symbol  RLFTF.  For  more  information,  visit  www.relieftherapeutics.com.  
Follow us on LinkedIn.


CONTACT:
RELIEF THERAPEUTICS Holding AG
Jack Weinstein
Chief Financial Officer and Treasurer  
contact@relieftherapeutics.com
FOR MEDIA/INVESTOR INQUIRIES:  
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

 
Ad hoc announcement pursuant to Art. 53 LR  
2


Disclaimer:  This  communication  expressly  or  implicitly  contains  certain  forward-looking  statements
concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks,
uncertainties and other factors, including (i) whether RELIEF THERAPEUTICS Holding SA will prevail in its
litigation  action  against  NeuroRx  over  the terms  of  the  Collaboration  Agreement,  (ii)  whether  aviptadil
will ever be approved in the U.S., the U.K., or the E.U. for the treatment of respiratory failure in patients
with  COVID-19,  and  (iii)  those  risks  discussed  in  RELIEF  THERAPEUTICS  Holding  SA's  press  releases  and
filings with the SIX, which could cause the actual results, financial condition, performance or achievements
of RELIEF  THERAPEUTICS  Holding  SA to  be materially different  from  any  future  results,  performance  or
achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding
SA is providing this communication as of this date and does not undertake to update any forward-looking
statements contained herein as a result of new information, future events or otherwise.


 

Nehmt euch mal die Zeit und lest den Valuation Report durch :-)



Relief Therapeutics Valuation Report
“What a Relief!”
Battling respiratory and rare disease and now NeuroRx

The integration of APR is progressing well, the AdVita acquisition successfully closed, and ACER-001 in urea cycle disorders has received FDA acceptance of filing with a 5 June 2022 PDUFA date and US patent allowance providing protection until 2036. Unfortunately, the ongoing dispute with NRx and its CEO Dr. Javitt has escalated to a lawsuit. A potential US Emergency Use Authorization grant for RLF-100 IV in COVID-19 induced ARDS in Q4 2021 would be transformational for Relief marking first commercial sales for RLF-100. Funding has been secured well into 2023.

Key catalysts include:
1. Potential US Emergency Use Authorization RLF-100 IV in COVID-19 ARDS (Q4 2021)
2. “AVICOVID-2” topline results RLF-100 INHALED in prevention COVID-19 related ARDS (Q4 2021)
3. Filing EU Conditional Marketing Authorization RLF-100 IV in COVID-19 ARDS (H1 2022)
vL Relief Therapeutics Valuation Report
Adobe Acrobat Document 1.8 MB
Download
https://www.valuationlab.com/app/download/...25OCT21.pdf?t=1635155372  

Also zum jetzigen Zeitpunkt abgelehnt.
Ist nicht unbedingt das Ende, könnte der Boden sein.
Oder auch nicht.

?
Ich mach es wie die Chinesen, 10 Jahre liegen lassen und dann einsammeln.
Ist natürlich schlecht für die bösen Börsianer.

 

Ist halt wie Lotto mit einer 50% Gewinnchance.
Um spielen zu können braucht es aber die Zulassung.
Ich erwarte nichts mehr, falls es doch noch steigen sollte hab ich auch nichts dagegen.
Schauen wir mal wie es bis Ende Jahr aussieht.  

Hoffen wir mal das sich die Pipeline mit Acer001 , Sentinox , Nexodyn usw.
positiv auf den Kurs auswirkt . Die Hoffnung stirbt bekanntlich zuletzt . Covid
knallt uns auch wieder mit voller Kraft um die Ohren und kein Ende in sicht .
Weiterhin zuversichtlich . Mal schauen was der Austausch im Management
bringt ! Allen noch eine entspannte Woche , passt auf euch auf und bleibt
gesund !!!  :-)
 
Ad hoc announcement pursuant to Art. 53 LR  
1

Relief Therapeutics Announces Transitions in Commercial Organization to
Implement Next Phase of Corporate Development

• Anthony M. Kim Appointed Senior Vice President and Head of U.S. Commercial Operations –
Seasoned Biotech Executive Brings Vast U.S. Commercial Launch Experience to Relief
• European and United Kingdom Commercial Operations Transitioned to Paolo Galfetti, President of
Relief Europe
• Chris Stijnen to Depart Relief

Geneva,  Switzerland,  November  9,  2021  –  RELIEF  THERAPEUTICS  Holding  SA  (SIX:  RLF,  OTCQB:  RLFTF)
(“Relief”),  a  biopharmaceutical  company  seeking  to  provide  patients  therapeutic  relief  from  serious
diseases  with  high  unmet  need,  announced  today  the  appointment,  effective  December  1,  2021,  of
Anthony  M.  Kim  as  Senior Vice  President  and  Head  of  U.S.  Commercial  Operations.    The  company also
reported  that  Chris  Stijnen,  Chief  Commercial  Officer  since  2020,  will  be  leaving  to  pursue  other
opportunities effective November 30, 2021. His duties regarding EU and UK commercial operations will
be assumed by Paolo Galfetti, President of Relief Europe, and the commercial team at Relief’s subsidiary,
APR Applied Pharma Research SA (“APR”).

“Our collaboration with Acer Therapeutics and strategic acquisitions of APR and AdVita Lifescience GmbH,
all  completed  in  2021,  have  allowed  us  to  significantly  expand  our  intellectual  property  position  and
pipeline,  while  bringing,  in-house,  a  number of  already  marketed  products,  such as APR’s flagship PKU
GOLIKE®, for the treatment of phenylketonuria,” stated Raghuram Selvaraju, Ph.D., Chairman of the Board
of  Directors  of  Relief.  “Anthony’s appointment  is  a  direct  acknowledgement  of  our  growing  corporate
needs,  our  commitment  to  our-long  term  growth,  and  our  plans  to  expand  availability  of  our  product
candidates in the U.S. including PKU GOLIKE®.  Anthony will also be a key part of Relief’s plan to optimize
the  commercial  success  of  ACER-001  in  collaboration  with  our  partner  Acer  Therapeutics.   As  a  proven
commercial  leader  with  extensive  launch  experience  gained  during  his  tenures  at  Novocure,  Alexion
Pharmaceuticals, Inc. and Genentech, Anthony is an invaluable addition and we are delighted to welcome
him to the Relief team.”

Dr. Selvaraju added, “I would also like to acknowledge Chris Stijnen’s extensive contributions during his
time  with  the  company.  His  efforts  over  the  past  year  have  been  instrumental  in  helping  to  drive  our
strategy and identify key opportunities for growth. We wish him all the best in his future endeavors.”

 
 
Ad hoc announcement pursuant to Art. 53 LR  
2


“I am excited and honored to be joining Relief, and to help further their mission of developing innovative
therapies  for  areas  of  great  unmet  medical  need,”  stated  Mr.  Kim. “I share the company’s vision for
improving the lives of patients living with acute and rare medical conditions.  I look forward to building
Relief’s presence in the U.S., and to living the values of the organization with integrity, sensitivity, and
humility each day.”

Prior  to  joining  Relief,  for  the  past  three  years,  Mr.  Kim  was  Vice  President,  Global  Commercial
Development at Novocure, where he led a 21-person team in the planning and U.S. marketing execution
for that  company’s Optune® and Optune Lua™, FDA-approved, therapeutic devices that deliver
alternating electrical fields to treat patients with Glioblastoma Multiforme and Mesothelioma.

From 2017 to 2018, he was Executive Director of Marketing at Ignyta (subsequently acquired by Roche),
during  which  time  he  led  the  development  of  the  commercial  launch  plan  for  entrectinib,  an  oral,
oncologic agent in pan-tumor clinical trials for patients with neurotrophic tyrosine receptor kinase (NTRK)
and ROS1 fusion-positive disease. From 2012 to 2017, Mr. Kim held positions of increasing responsibility
at Alexion Pharmaceuticals, Inc., most recently serving as Director, Head of U.S. Marketing,
Hypophosphatasia, where he managed the U.S. marketing efforts for the launch of Strensiq, a novel, first-
in-class enzyme replacement therapy for the treatment of hypophosphatasia, a rare inherited metabolic
bone disorder. Earlier, from 2004 to 2012, Mr. Kim held various positions at Genentech, including Product
Manager, Herceptin Marketing and Divisional Sales Manager, Rituxan Hematology.

Mr.  Kim  received  his  Bachelor  of  Arts  Degree  from  Harvard  University  and  a  Master  of  Business
Administration from The Wharton School.

ABOUT RELIEF
Relief  focuses  primarily  on  clinical-stage  programs  based  on molecules with  a  history  of  clinical  testing
and use in human patients or a strong scientific rationale. Relief’s drug candidate, RLF-100™ (aviptadil), a
synthetic  form  of  Vasoactive  Intestinal  Peptide  (VIP),  is  in  late-stage  clinical  testing  in  the  U.S.  for  the
treatment  of  respiratory  deficiency  due  to  COVID-19.  As  part  of  its  pipeline  diversification  strategy,  in
March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the
worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate
release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle
Disorders  and  Maple  Syrup  Urine  Disease.  In  addition,  Relief's  recently  completed  acquisitions  of  APR
Applied Pharma Research SA and AdVita Lifescience GmbH, bring to Relief a diverse pipeline of marketed
and development-stage programs.

 

Ad hoc von heute  :-)



Ad hoc announcement pursuant to Art. 53 LR  

1

Relief  Provides  Corporate  Update  and  Outlines  Plans  to  Advance  its  Diversified
Portfolio of Pipeline Candidates, Including RLF-100™ (Aviptadil)

Geneva, Switzerland, November 11, 2021 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF)
(“Relief”),  a  biopharmaceutical  company  seeking  to  provide  patients  therapeutic  relief  from  serious
diseases with high unmet need, today  provided a corporate update detailing, among other matters, its
ongoing clinical development and regulatory activities, as well as its plans to accelerate the maturation of
its pipeline.  

RLF-100TM

Relief  remains  committed to  the  development  of  RLF-100™  (aviptadil)  for the  treatment of  respiratory
complications of COVID-19 infection. A clinical program remains under way in Europe for inhalation-based
administration,  while  the  ACTIVE-3b/TESICO  study  sponsored  by  the  U.S.  National  Institutes  of  Health
(“NIH”) assessing the intravenous formulation and the I-SPY trial sponsored by Quantum Leap testing the
inhaled  formulation  also  remain  ongoing.  Further,  the  parent  company  of  Relief’s U.S.  collaboration
partner  has  publicly  reported  that  they  are  continuing  to  conduct  an  investigational  study  of  inhaled
aviptadil  in  the  U.S.  as  well.  In  addition,  Relief  continues  to  pursue  aviptadil  for  the  treatment  of
pulmonary sarcoidosis, and authorization to commence a phase 2 randomized, double-blinded, placebo-
controlled  clinical  trial  in  this  indication  was  recently  granted  by  the  German  medical  regulatory
authorities. In August 2021, Relief announced the receipt of U.S. Orphan Drug Designation for the use of
aviptadil in treatment of sarcoidosis. Relief also intends to explore the clinical utility of aviptadil in acute
respiratory distress  syndrome  (“ARDS”)  unrelated to COVID-19 infection, as well as in other pulmonary
disorders,  including  chronic  beryllium  disease  (“berylliosis”)  and  checkpoint  inhibitor-induced
pneumonitis (“CIP”), in which AdVita has filed pending patent claims.  Finally,  Relief  is  also  working  to
optimize the formulation of aviptadil.

As previously  reported, in October 2021 Relief  filed a lawsuit against  NeuroRx,  Inc.  ("NeuroRx") and its
Chief  Executive  Officer,  Dr.  Jonathan  Javitt,  for  multiple  breaches  of  the  Collaboration  Agreement
between Relief and NeuroRx relating to the development and commercialization of RLF-100™ (aviptadil).
The complaint alleges, among other breaches of the Collaboration Agreement, that NeuroRx has failed to
provide Relief with the full data set from NeuroRx's recently completed phase 2b/3 clinical trial evaluating
IV RLF-100™ (aviptadil) for the treatment of acute respiratory failure due to COVID-19 (which data and
information are required to be provided to Relief  by NeuroRx under the  Collaboration Agreement) and
has failed to allow Relief to have input into NeuroRx's U.S. development program. Without doubt, Relief

Ad hoc announcement pursuant to Art. 53 LR  

2

was  disappointed  that  Emergency  Use  Authorization  for  aviptadil  in  the  United  States  was  denied.
However,  this  decision  by FDA  does  not  affect  Relief's  commitment to  the  further  development  of  this
drug.  

U.S. Commercial Initiatives

Relief  is  focused on  establishing  its  U.S.  commercial operations  and  initiating market  rollout  of  its  lead
commercial product, PKU GOLIKE®, for the treatment of phenylketonuria (“PKU”). PKU GOLIKE® is a novel,
proprietary next-generation prolonged-release amino acid mix for use as a mainstay of PKU therapy and
is available in multiple formulations, including the innovative new PKU GOLIKE® KRUNCH™ tablets. Relief,
through  its  wholly  owned  subsidiary,  APR  Applied  Pharma  Research  SA  ("APR"),  currently  markets  this
product  in  Europe.  The  initiative  to  market  this  product  in  the  U.S.  will  be  led  by  Relief's  Head  of  U.S.
Commercial Operations, Anthony M. Kim, who has a lengthy track record of successful commercialization
of drugs aimed at rare and specialty disease indications in the U.S. market. Mr. Kim will be responsible for
spearheading the creation of Relief’s U.S.  commercial infrastructure and helping to optimize  the
introduction of the GOLIKE® product line.

Relief is also  working closely  with  its  collaboration partner Acer Therapeutics on the preparations for  a
potential launch of ACER-001, a proprietary, taste-masked formulation of sodium phenylbutyrate for the
treatment of Urea Cycle Disorders (“UCDs”). ACER-001 is the subject of a New Drug Application (“NDA”)
that has been accepted for review by the United States Food and Drug Administration (“FDA”) with a
Prescription Drug User Fee Act (PDUFA) approval decision action date of June 5, 2022. Additionally, Relief
is preparing to submit a Marketing Authorization Application (“MAA”) for ACER-001 to European and U.K.
regulatory agencies, which is expected to be filed during the first half of 2022. Moreover, Relief intends
to assess ACER-001 in a clinical program for Maple Syrup Urine Disease (“MSUD”) during 2022. Relief and
Acer  also  continue  to  explore  strategic  options  to  advance  the  optimization  of  ACER-001’s commercial
value in territories beyond the U.S., U.K. and Europe.

Other Initiatives

Relief intends to advance APR-TD011, a novel, proprietary, spray-based formulation of a hypotonic acid-
oxidizing solution with established wound healing and anti-microbial properties, for epidermolysis bullosa
(“EB”), a billion-dollar annual target market according to Knowledge Sourcing Intelligence. Relief believes
that APR-TD011 could prove a transformative solution for EB patients, who suffer from debilitating pain
due to large, chronic, constantly blistering skin wounds. APR-TD011 also inhibits the NF-kB pro-
inflammatory pathway and by inactivating matrix metalloproteases, known to mediate wound

Ad hoc announcement pursuant to Art. 53 LR  

3

inflammation.  Relief  believes  that  APR-TD011  could  improve  the  quality  of  life  of  EB  patients  by
accelerating wound healing and reducing the itching and pain linked to infections and inflammation.

Relief also possesses an array of other assets. These include SENTINOX, a novel nasal spray solution for
upper airway infections with viral pathogens including the SARS-CoV-2 virus, the causal agent of COVID-
19; Nexodyn AOS, an acid-oxidizing solution for treatment of chronic wounds (including foot ulcers); and
the PHYSIOMIMIC platform-enabled amino acid-based product candidates for an array of rare metabolic
disorders. Positive interim clinical data showing accelerated clearance of upper airway viral infection was
recently reported for SENTINOX in a randomized, placebo-controlled clinical trial. SENTINOX was certified
in Europe on February 16, 2021 as a Class III Medical Device (Certificate Nr. EPT 0477.MDD.21/4200.1).

Capital Resources

Relief currently has CHF45 million in cash, and, based on current financial current projections and available
cash, expects that it has sufficient resources to fund operations into late 2023, assuming timely approval
of ACER-001. Relief also expects that with a successful launch of ACER-001 and the potential expansion of
its  GOLIKE®  franchise  into  the  United  States,  Relief  could  achieve  positive  operating  cash  flow  status
during 2024. This could also be positively affected if Relief is successful in obtaining an approval to market
RLF-100™.

Finally, in early November, Relief took  the  first step to  establish a Level 1 American Depositary Receipt
(ADR) program in the United States by filing a registration statement on Form F-6 with the U.S. Securities
and  Exchange  Commission.  It  is  expected  that  Relief's  ADRs  will  begin  trading  in  the  over-the-counter
(OTC) market at some point after its registration statement becomes effective. Relief's ADR program will
complement its existing primary listing on the SIX Swiss Exchange. JPMorgan Chase Bank, N.A. has been
appointed  as  the  depositary  bank  for  the  Level  1  ADR  program.  This  filing  is  the  first  step  in  a  process
through which Relief hopes to transition its ADR program from a Level 1 ADR program to a Level 2 or a
Level 3 ADR program, with the ultimate goal of listing its ADRs on the NASDAQ Stock Market during the
first half of 2022.

ABOUT RELIEF
Relief  focuses  primarily  on  clinical-stage  programs  based  on molecules with  a  history  of  clinical  testing
and use in human patients or a strong scientific rationale. Relief’s lead drug candidate, RLF-100TM
(aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S.
for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy,  


Ad hoc announcement pursuant to Art. 53 LR  

4

in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the
worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate
release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle
Disorders  and  Maple  Syrup  Urine  Disease.  In  addition,  Relief's  recently  completed  acquisitions  of  APR
Applied Pharma Research SA and AdVita Lifescience GmbH bring to Relief a diverse pipeline of marketed
and development-stage programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in
the  U.S.  on  OTCQB  under  the  symbol  RLFTF.  For  more  information,  visit  www.relieftherapeutics.com.  
Follow us on LinkedIn.  
CONTACT:
RELIEF THERAPEUTICS Holding AG
Jack Weinstein
Chief Financial Officer and Treasurer  
contact@relieftherapeutics.com
FOR MEDIA/INVESTOR INQUIRIES:  
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

Disclaimer:  This  communication  expressly  or  implicitly  contains  certain  forward-looking  statements
concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks,
uncertainties  and  other  factors,  including  (i)  whether  RELIEF  THERAPEUTICS  Holding  SA  can  obtain
approval to market RLF-100™ (aviptadil) and the effect on its efforts in that regard of the pending lawsuit
against  NeuroRx  and  its  CEO,  (ii) whether  ACER-001 will  be  approved  for  commercialization  in the  U.S.
and successfully commercialized if approved, (iii) whether PKU GOLIKE® can be successfully marketed in
the U.S., (iv) whether RELIEF THERAPEUTICS Holding SA has sufficient cash resources to fund its operations
into late 2023 and whether RELIEF THERAPEUTICS Holding SA can become cash flow positive by 2024, (v)
whether  RELIEF  THERAPEUTICS  Holding  SA  will  be  able  to  transition  its  ADR  program  from  a  Level  1
program to a Level 2 or a Level 3 program and up list its ADRs to the NASDAQ Stock Market, and (vi) those
risks discussed in RELIEF THERAPEUTICS Holding SA's press releases and filings with the SIX, which could
cause  the  actual  results,  financial  condition,  performance  or  achievements  of  RELIEF  THERAPEUTICS
Holding SA to be materially different from any future results, performance or achievements expressed or
implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this
communication  as  of  this  date  and  does  not  undertake  to  update  any  forward-looking  statements
contained herein as a result of new information, future events or otherwise.
 

Ist das das Licht am Ende des Tunnels ?
https://www.gov.uk/guidance/innovative-licensing-and-access-pathway
....und das Ende der pharmahörigen FDA !
 

Endlich mal eine Positive Nachricht, diese sollte den Aufschwung wieder auf 50 Rappen geben.
 

https://www.finanznachrichten.de/...a-u-s-food-and-drug-admin-023.htm  

 
Ad hoc announcement pursuant to Art. 53 LR  
1

Relief Reports that its U.S. Collaboration Partner has Announced it has Received
a U.S. Food and Drug Administration Review of Aviptadil Manufacturing
Information

Geneva, Switzerland, November 12, 2021 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF)
(“Relief”),  a  biopharmaceutical  company  seeking  to  provide  patients  therapeutic  relief  from  serious
diseases with high unmet need, reported today that the parent company of its U.S. collaboration partner,
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx”), has issued a press release announcing receipt of the
U.S.  Food and Drug Administration’s (FDA) response to NRx’s October 8,  2021  submission  of  updated
manufacturing information for aviptadil. According to the press release, the FDA review allows for high
volume  production  of  aviptadil.  The  press  release  also  reports  that  the  shelf  life  of  aviptadil  has  been
extended from 62 days to 150 days. The related NRx press release can be accessed through the following
link.

ABOUT RELIEF
Relief  focuses  primarily  on  clinical-stage  programs  based  on molecules with  a  history  of  clinical  testing
and use in human patients or a strong scientific rationale. Relief’s lead drug candidate, RLF-100™
(aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S.
for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy,
in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the
worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate
release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle
Disorders  and  Maple  Syrup  Urine  Disease.  In  addition,  Relief's  recently  completed  acquisitions  of  APR
Applied Pharma Research SA and AdVita Lifescience GmbH, bring to Relief a diverse pipeline of marketed
and development-stage programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in
the  U.S.  on  OTCQB  under  the  symbol  RLFTF.    For  more  information,  visit  www.relieftherapeutics.com.  
Follow us on LinkedIn.


 
Ad hoc announcement pursuant to Art. 53 LR  
2


CONTACT:
RELIEF THERAPEUTICS Holding SA
Jack Weinstein
Chief Financial Officer and Treasurer  
contact@relieftherapeutics.com

FOR MEDIA/INVESTOR INQUIRIES:  
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com


Disclaimer:  This  communication  expressly  or  implicitly  contains  certain  forward-looking  statements
concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks,
uncertainties and other factors, including (i) whether aviptadil will ever be approved in the U.S., the U.K.,
or the E.U. for the treatment of respiratory failure in patients with COVID-19, and (ii) those risks discussed
in RELIEF THERAPEUTICS Holding SA's press releases and filings with the SIX, which could cause the actual
results,  financial  condition,  performance  or  achievements  of  RELIEF  THERAPEUTICS  Holding  SA  to  be
materially different from any future results, performance or achievements expressed or implied by such
forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this
date and does not undertake to update any forward-looking statements contained herein as a result of
new information, future events or otherwise.
 

https://www.facebook.com/photo/...clgT-Aorl4EmoHOe02w&__tn__=EH-R  

https://www.gesundheitsindustrie-bw.de/en/article/...nduced-pneumonia

https://covid19.who.int/  

wenn ihr im Suchfenster Aviptadil eingebt ! Allen noch einen schönen Sonntag !  :-)

https://trialsearch.who.int/  

https://www.precisionvaccinations.com/vaccines/...iptadil-therapeutic  

Ensovibep von Molecular Partners ist nicht mehr im Rennen. Die Zwischenanalyse von ACTIV 3 (NCT04501978) zeigte keine Aktivität...

Wir sind immer noch hier und unser ACTIV3b rekrutiert immer noch.

 

https://investors.molecularpartners.com/...v-3-global-clinical-study/  

https://www.cash.ch/news/top-news/...mmt-der-boerse-unter-die-1855930

vieleicht ein Zock wert ?  :-)  

Der Pharmariese beendet seine Partnerschaft mit Atea, die im Rahmen der Entwicklung einer Coronapille gestartet hatte.

(AWP) Der Pharmakonzern Roch hat nach enttäuschenden Studien-Ergebnissen die Zusammenarbeit mit dem US-Unternehmen Atea beendet. Nach einer gründlichen Analyse der derzeitigen Covid-19-Behandlungslandschaft habe man die schwierige Entscheidung getroffen, die Partnerschaft mit Atea für das AT-527-Programm zu beenden, um sich auf andere COVID-19-Aktivitäten zu konzentrieren, heisst es in einer Stellungnahme von Roche (ROG 369.15 +0.04%), die AWP vorliegt.

Mit Beendigung der Partnerschaft werden die Rechte und Lizenzen, die Atea Roche im Rahmen der strategischen Zusammenarbeit gewährt hat, an Atea zurückgegeben. Diese Entscheidung kommt, nachdem Atea vor etwa einem Monat mit dem Hoffnungsträger AT-527, der sogenannten Corona-Pille, in einer Phase-II-Studie die gesteckten Ziele nicht erreicht hatte.

Wie Roche weiter mitteilte, will der Konzern die Entwicklung anderer Covid-19-Behandlungs- und Diagnoseoptionen fortsetzen. Dazu zählen etwa die Antikörperkombination Ronapreve (Casirivimab und Imdevimab), die Roche in Zusammenarbeit mit Regeneron betreibt, sowie Actemra/RoActemra (Tocilizumab) von Roche selbst.

Atea wiederum teilte mit, das laufende klinische Phase-III-Studienprogramm MORNINGSKY mit AT-527 weiter voranzutreiben.  

 
Ad hoc announcement pursuant to Art. 53 LR  

1
Relief Therapeutics Launches Level 1 ADR Program in the United States

Geneva, Switzerland, November 18, 2021 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF)
(“Relief”), announced today that its Form F-6 registration statement has become effective, and that Relief
has launched its Level 1 American Depositary Receipt ("ADR") program in the United States (“U.S.”). It is
expected that Relief's ADRs will begin trading on the over-the-counter ("OTC") market today, November
18, 2021, under the trading symbol ("RLFTY"). Relief's ADR program will complement its existing primary
listing  of  ordinary  shares  on  the  SIX  Swiss  Exchange  ("SIX").  J.P.  Morgan  has  been  appointed  as  the
depositary bank for the Level 1 ADR program.

An  ADR  is  a  negotiable  receipt,  resembling  a  stock  certificate,  that  is  issued  by  a  U.S.  depositary  bank
appointed  by  a  company  to  evidence  one  or  more  American  Depositary  Shares  ("ADSs").  In  the  case  of
Relief's ADRs, each ADS will represent one hundred and fifty (150) of Relief's ordinary shares. ADRs allow
U.S.  investors  to  buy  shares  in  foreign  companies  without  the  need  for  cross-border  or  cross-currency
transactions. They are priced in U.S. dollars and can be traded like shares of U.S.-based companies listed
on the OTC market.

Under the program, the owners and holders of ADSs will have the same rights to dividends and distributions
and voting powers as the holders of Relief's ordinary shares subject, however, to enforcement procedures
provided in the deposit agreement entered into by and among Relief, J.P. Morgan, as the depositary, and
the owners and holders of ADSs.

The establishment of the program by Relief is not a new offering of securities, and the ADRs will be based
on  the  Relief  ordinary  shares  currently  in  issue.  Therefore,  Relief  will  receive  no  proceeds  from  the
establishment  of  the  program.  However,  Relief's  goal  is  to  take  the  necessary  steps  in  the  future  to
transition from a Level 1 ADR program to a Level 2 or a Level 3 ADR program, with the ultimate goal of
listing its ADRs on the Nasdaq Stock Market during the first half of 2022. There can be no assurance that
Relief will be successful in those efforts.

Instructions for converting Relief ordinary shares into ADRs are posted on Relief's website at
https://www.relieftherapeutics.com/investor-relations or CLICK HERE.

ABOUT RELIEF

Relief  focuses  primarily  on  clinical-stage  programs  based  on molecules with  a  history  of  clinical  testing
and use in human patients or a strong scientific rationale. Relief’s drug candidate, RLF-100™ (aviptadil), a
synthetic form of Vasoactive Intestinal Peptide ("VIP"), is in late-stage clinical testing in the U.S. for the
treatment  of  respiratory  deficiency  due  to  COVID-19.  As  part  of  its  pipeline  diversification  strategy,  in
March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the
worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate
 
Ad hoc announcement pursuant to Art. 53 LR  

2
release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle
Disorders  and  Maple  Syrup  Urine  Disease.  In  addition,  Relief's  recently  completed  acquisitions  of  APR
Applied Pharma Research SA and AdVita Lifescience GmbH, bring to Relief a diverse pipeline of marketed
and development-stage programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in
the  U.S.  on  OTCQB  under  the  symbol  RLFTF.    For  more  information,  visit  www.relieftherapeutics.com.  
Follow us on LinkedIn.


CONTACT:
RELIEF THERAPEUTICS Holding SA
Jack Weinstein
Chief Financial Officer and Treasurer  
contact@relieftherapeutics.com

FOR MEDIA/INVESTOR INQUIRIES:  
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com


Disclaimer:  This  communication  expressly  or  implicitly  contains  certain  forward-looking  statements
concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks,
uncertainties and other factors, including (i) whether a market will develop for Relief's ADRs, (ii) whether,
if Relief's ADRs are traded in the U.S., they will become eligible to be listed on the NASDAQ Stock Market,
and  the  timing  of  any  such  listing,  and  (iii)  those  risks  discussed  in  RELIEF  THERAPEUTICS  Holding  SA's
press releases  and filings with the SIX,  which could cause the actual results, financial condition,
performance  or  achievements  of  RELIEF  THERAPEUTICS  Holding  SA  to  be  materially  different  from  any
future results, performance or achievements expressed or implied by such forward-looking statements.
RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake
to update any forward-looking statements contained herein as a result of new information, future events
or otherwise.


 
Ad-hoc-Mitteilung gemäss Art. 53 LR  

1
Relief Therapeutics lanciert Level 1 ADR-Programm in den Vereinigten Staaten

Genf, Schweiz, 18. November 2021 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF)
("Relief"), gab heute bekannt, dass seine Registrierungserklärung nach Form F-6 wirksam geworden ist und dass Relief
sein Level 1 American Depositary Receipt ("ADR") Programm in den Vereinigten Staaten ("U.S.") gestartet hat. Es wird erwartet
Es wird erwartet, dass die ADRs von Relief ab heute, dem 18. November 2021, im Freiverkehr ("OTC"-Markt)
18. November 2021, unter dem Handelssymbol ("RLFTY"). Das ADR-Programm von Relief wird die bestehende Primärnotierung
Notierung von Stammaktien an der SIX Swiss Exchange ("SIX") ergänzen.  J.P. Morgan wurde als Depotbank für die
Depotbank für das Level 1 ADR-Programm ernannt.

Ein ADR ist ein begebbarer Beleg, der einem Aktienzertifikat ähnelt und von einer US-Depotbank ausgegeben wird
ausgestellt wird, um eine oder mehrere American Depositary Shares ("ADS") zu verbriefen.  Im Fall von
ADRs von Relief repräsentiert jedes ADS einhundertfünfzig (150) Stammaktien von Relief. ADRs ermöglichen
US-Investoren den Kauf von Aktien ausländischer Unternehmen ohne die Notwendigkeit grenzüberschreitender oder währungsübergreifender
Transaktionen. Sie werden in US-Dollar gepreist und können wie Aktien von in den USA ansässigen Unternehmen gehandelt werden, die
auf dem OTC-Markt gehandelt werden.

Im Rahmen des Programms haben die Eigentümer und Inhaber von ADSs die gleichen Rechte auf Dividenden und Ausschüttungen
und Stimmrechte wie die Inhaber der Stammaktien von Relief, jedoch vorbehaltlich der Durchsetzungsverfahren
die in der Hinterlegungsvereinbarung zwischen Relief, J.P. Morgan als Hinterlegungsstelle und den
den Eigentümern und Inhabern der ADSs.

Die Einrichtung des Programms durch Relief ist kein neues Angebot von Wertpapieren, und die ADRs werden auf den
auf den derzeit ausgegebenen Relief-Stammaktien basieren.  Daher wird Relief keine Erlöse aus dem Programm erhalten.
Erlös aus der Einrichtung des Programms.  Es ist jedoch das Ziel von Relief, in Zukunft die notwendigen Schritte zu unternehmen, um
von einem ADR-Programm der Stufe 1 zu einem ADR-Programm der Stufe 2 oder 3 überzugehen, mit dem letztendlichen Ziel der
ADRs in der ersten Hälfte des Jahres 2022 am Nasdaq Stock Market zu notieren. Es kann nicht garantiert werden, dass
Relief bei diesen Bemühungen erfolgreich sein wird.

Anweisungen für die Umwandlung von Relief-Stammaktien in ADRs finden Sie auf der Website von Relief unter
https://www.relieftherapeutics.com/investor-relations oder HIER KLICKEN.

ÜBER RELIEF

Relief konzentriert sich in erster Linie auf Programme im klinischen Stadium, die auf Molekülen basieren, die in der Vergangenheit bereits klinisch getestet
klinischen Erprobung und Anwendung bei menschlichen Patienten oder einer starken wissenschaftlichen Grundlage. Der Arzneimittelkandidat von Relief, RLF-100™ (Aviptadil), eine
synthetische Form des vasoaktiven intestinalen Peptids ("VIP"), befindet sich in den USA in der späten Phase der klinischen Prüfung für die
Behandlung von Atemschwäche aufgrund von COVID-19.  Im Rahmen seiner Strategie zur Diversifizierung der Pipeline hat Relief im
März 2021 eine Kooperations- und Lizenzvereinbarung mit Acer Therapeutics für die weltweite
weltweite Entwicklung und Vermarktung von ACER-001. ACER-001 ist ein geschmacksmaskierter und sofortiger
 
Ad-hoc-Mitteilung gemäss Art. 53 LR  

2
Pulverformulierung von Natriumphenylbutyrat (NaPB) zur Behandlung von Harnstoffzyklusstörungen
Harnstoffzyklus-Störungen und der Ahornsirup-Urin-Krankheit.  Darüber hinaus haben die kürzlich abgeschlossenen Übernahmen von APR
Applied Pharma Research SA und AdVita Lifescience GmbH, bringt Relief eine vielfältige Pipeline von vermarkteten
und Programmen im Entwicklungsstadium.

RELIEF THERAPEUTICS Holding SA ist an der SIX Swiss Exchange unter dem Symbol RLF notiert und in den
OTCQB in den USA unter dem Symbol RLFTF notiert.    Weitere Informationen finden Sie unter www.relieftherapeutics.com.  
Folgen Sie uns auf LinkedIn.


KONTAKT:
RELIEF THERAPEUTICS Holding SA
Jack Weinstein
Finanzvorstand und Schatzmeister  
contact@relieftherapeutics.com

FÜR MEDIEN-/INVESTORENANFRAGEN:  
Rx-Kommunikationsgruppe
Michael Müller
+1-917-633-6086
mmiller@rxir.com


Haftungsausschluss: Diese Mitteilung enthält ausdrücklich oder stillschweigend bestimmte zukunftsgerichtete Aussagen
über RELIEF THERAPEUTICS Holding SA. Solche Aussagen beinhalten bestimmte bekannte und unbekannte Risiken,
Ungewissheiten und andere Faktoren, einschließlich (i) ob sich ein Markt für die ADRs von Relief entwickeln wird, (ii) ob,
wenn die ADRs von Relief in den USA gehandelt werden, sie zur Notierung an der NASDAQ-Börse zugelassen werden,
und der Zeitpunkt einer solchen Notierung, und (iii) die Risiken, die in den Pressemitteilungen von RELIEF THERAPEUTICS Holding SA
Pressemitteilungen und Einreichungen bei der SIX beschriebenen Risiken, die dazu führen könnten, dass die tatsächlichen Ergebnisse, die Finanzlage,
von RELIEF THERAPEUTICS Holding SA wesentlich von den in der Zukunft
zukünftigen Ergebnissen, Leistungen oder Errungenschaften, die in solchen zukunftsgerichteten Aussagen ausgedrückt oder impliziert werden, erheblich abweichen.
RELIEF THERAPEUTICS H

Übersetzt mit www.DeepL.com/Translator (kostenlose Version)
 

https://youtu.be/PPEUWrjK1I8  

Bisschen ruhig geworden hier, ist Relief am Freitag Ende?  

 
Ad hoc announcement pursuant to Art. 53 LR  

1
Relief  Therapeutics  and  InveniAI  Sign  a  Strategic  Collaboration  Agreement  to
Identify New Product Development Opportunities using Artificial Intelligence

Geneva, Switzerland, November 24, 2021 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF,
RLFTY)  (“Relief”),  announced  today  that  it  has  signed  a  collaboration  agreement  (the  “Collaboration”)
with  InveniAI  LLC  (“InveniAI”),  a  U.S.  based  company  that  has  pioneered  the  application  of  artificial
intelligence and machine learning across biopharma and other industries, in order to identify promising
drug candidates to treat rare and specialty diseases.  

Under the terms of the Collaboration,  InveniAI will use  its proprietary  platform for the identification of
potential  pharmaceutical  product  opportunities  using  its  Pharma Big Data Innovation Lab (“Platform”),
consisting of (i) its proprietary AlphaMeld® platform, a cloud-based Artificial Intelligence (“AI”) platform
that utilizes proprietary machine  learning and deep learning based neural networks to identify product
opportunities  in  therapeutic  areas,  (ii)  its  cross-functional  teams  at  its  Integrated  Center  of  Excellence,
and (iii) domain expertise, to generate novel pharmaceutical opportunities and the related development
pathway for the development of such concepts.
In the Collaboration, it is expected that InveniAI will utilize its Platform to navigate the volume of data for
all  regulatory  agency  approved  drugs  and  their  associated  active  ingredients  (Active  Pharmaceutical
Ingredient  (“API”))  to  identify  potential  rare  and  specialty  disease  indications  for  development  and
commercialization by Relief (“Product Concepts”). InveniAI will seek to prioritize top Product Concepts,
associated diseases, scientific  packages and evidence to support the potential drug development
opportunities by Relief. Relief anticipates InveniAI’s Platform will complement its wholly owned subsidiary
APR Applied Pharma Research SA’s  existing  capabilities  in  research  and  development  and  drug
reformulation.  Based  on  product  leads  developed  by  InveniAI,  Relief  hopes  to  develop  proprietary
versions of existing drugs, and to protect those drugs with long-lived intellectual property and defensible
patent claims.

Under the terms of the Collaboration, Relief will pay InveniAI an initial up-front fee, success milestones
and commercialization royalties for the full development program. Additional financial details were not
disclosed.

“We  believe  that  the  addition  of  InveniAI’s  AI-powered  capabilities  will  meaningfully  complement  our
existing  drug  development  efforts.  AI  is  becoming  an  increasingly  important  tool  in  identifying  and
screening  new  drug  projects  and  Relief  intends  to  fully  leverage  this  promising  technology,”  stated
Raghuram (Ram)  Selvaraju,  Chairman of Relief. “In  partnering  with  InveniAI, we are  accessing decades’
worth of expertise which has already led to successful drug re-innovation (e.g., vilazodone for treatment
of depression and dexmedetomidine for treatment of agitation) and a proven platform that has been the
basis of multiple partnerships with established companies. We believe that our work with InveniAI could
generate multiple promising additions to our pipeline that may represent capital-efficient, cost-effective
 
Ad hoc announcement pursuant to Art. 53 LR  

2
and  risk-mitigated  approaches  to  product  development.  In  focusing  on  the  optimization  of  existing
approved APIs, we hope to ensure well-established clinical safety and tolerability for the product concepts
identified at inception, giving us a running start in pursuing development of novel uses for these drugs. In
our view, this approach will  enable us to rapidly  and efficiently execute innovation that brings relief  to
patients suffering from severe and debilitating conditions.”

ABOUT RELIEF
Relief  focuses  primarily  on  clinical-stage  programs  based  on molecules with  a  history  of  clinical  testing
and use in human patients or a strong scientific rationale. Relief’s drug candidate, RLF-100™ (aviptadil), a
synthetic  form  of  Vasoactive  Intestinal  Peptide  (VIP),  is  in  late-stage  clinical  testing  in  the  U.S.  for  the
treatment  of  respiratory  deficiency  due  to  COVID-19.  As  part  of  its  pipeline  diversification  strategy,  in
March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the
worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate
release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle
Disorders  and  Maple  Syrup  Urine  Disease.  In  addition,  Relief's  recently  completed  acquisitions  of  APR
Applied Pharma Research SA and AdVita Lifescience GmbH bring to Relief a diverse pipeline of marketed
and development-stage programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in
the  U.S.  on  OTCQB  under  the  symbol  RLFTF.    For  more  information,  visit  www.relieftherapeutics.com.  
Follow us on LinkedIn.

CONTACT:
RELIEF THERAPEUTICS Holding SA
Jack Weinstein
Chief Financial Officer and Treasurer  
contact@relieftherapeutics.com

FOR MEDIA/INVESTOR INQUIRIES:  
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

Disclaimer:  This  communication  expressly  or  implicitly  contains  certain  forward-looking  statements
concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks,
uncertainties and other factors, including (i) whether InveniAI will bring to RELIEF THERAPEUTICS Holding
SA drug candidates that can be successfully developed by RELIEF THERAPEUTICS Holding SA,  (ii) whether
RELIEF  THERAPEUTICS  Holding  SA  will  successfully  develop  and  ultimately  market  any  drug  candidate
identified by InveniAI, and (iii) those risks discussed in RELIEF THERAPEUTICS Holding SA's press releases
and  filings  with  the  SIX,  which  could  cause  the  actual  results,  financial  condition,  performance  or
achievements  of  RELIEF  THERAPEUTICS  Holding  SA  to  be  materially  different  from  any  future  results,
performance or achievements expressed or implied by such forward-looking statements. RELIEF
THERAPEUTICS  Holding  SA  is  providing  this  communication  as  of  this  date  and  does  not  undertake  to
update any forward-looking statements contained herein as a result of new information, future events or
otherwise.